Senju Pharmaceutical partnered with Kiora Pharmaceuticals, gaining an option agreement to develop KIO-301 and seeking commercialization in key Asian markets including China.
2 reports, 2 independent
Updated Aug 7
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Senju Pharmaceutical partnered with Kiora Pharmaceuticals, gaining an option agreement to develop KIO-301 and seeking commercialization in key Asian markets including China.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Senju Pharmaceutical (United States)
company in Woodland Hills, United States
Nothing else this week.
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- NewsfileKiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases Encinitas, California--(Newsfile Corp. - August 8, 20